
Forgiveness charts the ability of a drug or regimen to withstand non-adherence without negative clinical consequences. The study aimed to determine the influence of regimen length, regimen drugs, and dosing, and when during treatment, non-adherence occurs on the forgiveness of antituberculosis regimens. With the current appetite for and progress toward shorter drug-sensitive tuberculosis regimens worldwide, the present investigation offers reassurance that shorter regimens are not necessarily less forgiving of non-adherence. However, given the importance of continuation phase adherence, patient support during this period should not be neglected.
Like
Save
Share